Abstract:
Renzo Tomellini, DG Research's head of the nanotechnology unit, concedes that more in-depth research is needed. "Studies are now launched to assess possible risks. Several studies are ongoing at EU and Member States level, see e.g. the initiative of the Royal Society in the UK," he told EurActiv. "The Commission is already funding three projects on the impact of nanoparticles on the human body and also in the future a high priority will be given to risk assessment in this area."